Ocular Therapeutix Q4 DEXTENZA rev $13.9M (+14% YoY); guides 2023 rev $55-60M; net loss $71M

OCULAR THERAPEUTIX, INC

DEXTENZA net product revenue Q4 2022 $13.9M (+14% YoY, +17% QoQ); full year $50.5M (+20% YoY).
Total net revenue full year 2022 $51.5M (+18% YoY); net loss $(71.0)M vs $(6.6)M in 2021 (includes $5.2M non-cash item).
Cash and equivalents $102.3M at Dec 31, 2022; company expects cash runway to mid-2024.
OTX-TKI Phase 1 wet AMD: 73% rescue-free at 10 months; 92% reduction in treatment burden; pivotal trial planned Q3 2023.
OTX-TIC Phase 2 glaucoma top-line data expected Q4 2023; Phase 1 diabetic retinopathy trial initiated Dec 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OCULAR THERAPEUTIX, INC reported the fourth quarter and year ended December 31, 2022 results: revenue $51.5 million.

Period: the fourth quarter and year ended December 31, 2022
Revenue: $51.5 million
Result: reported results

Exact text from the filing

intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected in Q4 2023 Total Net Revenue for Full Year 2022 was $51.5 million, Representing Growth of 18% Over the Prior Year DEXTENZA ® Net Product Revenue in the Fourth Quarter of 2022 was $13.9 million, Representing Growth of approximately 17% Over

View on SEC.gov

Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-23-028993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.